Compare AbCellera Biologics Inc (ABCL) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Phillips 66 — how do they compare? AbCellera Biologics Inc trades at $7.15 (market cap $2.35B), while Phillips 66 trades at $187.22 (market cap $71.70B). The key difference: Phillips 66 is far larger — about 30.5× AbCellera Biologics Inc's market cap, and Phillips 66 pays a 2.84% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | PSX | |
|---|---|---|
Market Cap | $2.35B | $71.70B |
Sector | Health | Energy |
52-Week High | $8.12 | $188.28 |
52-Week Low | $2.78 | $118.37 |
Enterprise Value | $1.99B | $93.68B |
Dividend Yield | — | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Phillips 66 (PSX) trades at $178.84, up 1.37% with a bullish technical signal and strong analyst consensus. The stock shows improving fundamentals with recent earnings beats, a 3.07% net margin, and attractive valuation at P/E 17.52 and P/S 0.54. Recent news highlights resilience amid softer oil prices, supported by diversified operations and a $1.27 dividend payment.
Outlook remains positive with a $190.38 price target, though risks include refining volatility from Hormuz disruptions and declining revenue trends. The stock offers value through stable cash flow and dividend income, but investors should monitor geopolitical impacts on earnings and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
